Ganoderma lucidum Combined with the EGFR Tyrosine Kinase Inhibitor, Erlotinib Synergize to Reduce Inflammatory Breast Cancer Progression

The high incidence of resistance to Tyrosine Kinase Inhibitors (TKIs) targeted against EGFR and downstream pathways has increased the necessity to identify agents that may be combined with these therapies to provide a sustained response for breast cancer patients. Here, we investigate the therapeuti...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Cancer
Main Authors: Suárez-Arroyo, Ivette J., Rios-Fuller, Tiffany J., Feliz-Mosquea, Yismeilin R., Lacourt-Ventura, Mercedes, Leal-Alviarez, Daniel J., Maldonado-Martinez, Gerónimo, Cubano, Luis A., Martínez-Montemayor, Michelle M.
Formato: Artigo
Idioma:Inglês
Publicado: Ivyspring International Publisher 2016
Assuntos:
Research Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4780125/
https://ncbi.nlm.nih.gov/pubmed/26958085
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/jca.13599
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares